Travere Therapeutics (TVTX) Short-term Investments (2013 - 2018)
Travere Therapeutics posted quarterly Short-term Investments of $166.4 million for Q2 2018, down 19.51% year-on-year from $206.7 million in Q2 2017, and down 18.01% on a QoQ basis from $202.9 million in Q1 2018.
Travere Therapeutics (TVTX) has 6 years of Short-term Investments data on file, last reported at $166.4 million in Q2 2018.
- For the quarter ending Q2 2018, Short-term Investments fell 19.51% year-over-year to $166.4 million; the trailing twelve-month figure through Jun 2018 stood at $166.4 million (down 19.51% YoY), and the FY2017 full-year result was $201.2 million, down 6.35% from the prior year.
- Short-term Investments for Q2 2018 stood at $166.4 million, down from $202.9 million in the prior quarter.
- Across five years, Short-term Investments topped out at $250.4 million in Q3 2016 and bottomed at $5.9 million in Q2 2015.
- The 5-year median for Short-term Investments is $199.7 million (2016), against an average of $148.3 million.
- The widest annual swing landed in 2014, when Short-term Investments surged 7085.29%; it then retreated 19.51% in 2018.
- A 5-year view of Short-term Investments shows it stood at $9.6 million in 2014, then jumped by 1907.11% to $191.8 million in 2015, then gained by 12.03% to $214.9 million in 2016, then retreated by 6.35% to $201.2 million in 2017, then retreated by 17.32% to $166.4 million in 2018.
- The last three Short-term Investments figures came in at $166.4 million (Q2 2018), $202.9 million (Q1 2018), and $201.2 million (Q4 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 166.38 Mn |
| Mar 31, 2018 | 202.94 Mn |
| Dec 31, 2017 | 201.24 Mn |
| Sep 30, 2017 | 204.88 Mn |
| Jun 30, 2017 | 206.72 Mn |
| Mar 31, 2017 | 206.29 Mn |
| Dec 31, 2016 | 214.87 Mn |
| Sep 30, 2016 | 250.41 Mn |
| Jun 30, 2016 | 200.36 Mn |
| Mar 31, 2016 | 199.08 Mn |
| Dec 31, 2015 | 191.80 Mn |
| Sep 30, 2015 | 94.68 Mn |
| Jun 30, 2015 | 5.86 Mn |
| Mar 31, 2015 | 6.16 Mn |
| Dec 31, 2014 | 9.56 Mn |
| Sep 30, 2014 | 11.93 Mn |
| Dec 31, 2013 | 132,994.00 |